Literature DB >> 6693169

Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine.

M M Levine, R E Black, M L Clements, C Lanata, S Sears, T Honda, C R Young, R A Finkelstein.   

Abstract

Texas Star-SR, an A- B+ mutant derived by nitrosoguanidine treatment from Vibrio cholerae El Tor Ogawa strain 3083, was fed to 68 volunteers as an oral vaccine in doses of 10(5) to 5 X 10(10) organisms with NaHCO3. Sixteen (24%) vaccinees experienced some loose stools (unrelated to vaccine dose), but in only one did the total stool volume exceed 1.0 liter. The vaccine strain was cultured from duodenal fluid of 35 of 46 (76%) persons who ingested doses of 10(8) organisms or greater. No A+ B+ toxinogenic revertants were found among 456 clinical isolates tested. Sixty-three vaccinees (93%) manifested seroconversions of vibriocidal antibody, whereas only 20 (29%) had significant rises in serum antitoxin titers. Paired intestinal fluids from 41 volunteers showed significant rises of secretory immunoglobulin A against lipopolysaccharide (29%), Ogawa outer membrane preparation (29%), and toxin (12%) antigens. In challenge studies with pathogenic V. cholerae El Tor Ogawa and El Tor Inaba, the attack rate in vaccinees (7 of 25) was significantly lower than in controls (18 of 25) (vaccine efficacy, 61%); furthermore, the diarrheal stool volume in vaccinees was significantly less than that in controls (P less than 0.01). Texas Star-SR served as a prototype to investigate the concept of immunoprophylaxis by means of attenuated strains as oral vaccines. These observations provide an invaluable background for planning future studies with newly developed attenuated strains prepared by recombinant DNA techniques.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6693169      PMCID: PMC264327          DOI: 10.1128/iai.43.2.515-522.1984

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  Not one but four possible oral vaccines for cholera under study.

Authors:  J Henahan
Journal:  JAMA       Date:  1982-10-22       Impact factor: 56.272

2.  Observations on the pathogenic properties of the K88, Hly and Ent plasmids of Escherichia coli with particular reference to porcine diarrhoea.

Authors:  H W Smith; M A Linggood
Journal:  J Med Microbiol       Date:  1971-11       Impact factor: 2.472

3.  Studies on toxinogenesis in Vibrio cholerae. III. Characterization of nontoxinogenic mutants in vitro and in experimental animals.

Authors:  R K Holmes; M L Vasil; R A Finkelstein
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

4.  Vibrio cholerae adherence and colonization in experimental cholera: electron microscopic studies.

Authors:  E T Nelson; J D Clements; R A Finkelstein
Journal:  Infect Immun       Date:  1976-08       Impact factor: 3.441

5.  Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae.

Authors:  M L Clements; M M Levine; C R Young; R E Black; Y L Lim; R M Robins-Browne; J P Craig
Journal:  J Infect Dis       Date:  1982-04       Impact factor: 5.226

6.  Oral immunization of dogs with purified cholera toxin, crude cholera toxin, or B subunit: evidence for synergistic protection by antitoxic and antibacterial mechanisms.

Authors:  N F Pierce; W C Cray; J B Sacci
Journal:  Infect Immun       Date:  1982-08       Impact factor: 3.441

Review 7.  Travellers' diarrhoea: prospects for successful immunoprophylaxis.

Authors:  M M Levine
Journal:  Scand J Gastroenterol Suppl       Date:  1983

8.  Longitudinal studies of infectious diseases and physical growth of children in rural Bangladesh. II. Incidence of diarrhea and association with known pathogens.

Authors:  R E Black; K H Brown; S Becker; A R Alim; I Huq
Journal:  Am J Epidemiol       Date:  1982-03       Impact factor: 4.897

9.  Identification and preliminary characterization of Vibrio cholerae outer membrane proteins.

Authors:  J T Kelley; C D Parker
Journal:  J Bacteriol       Date:  1981-02       Impact factor: 3.490

10.  Field trials of monovalent Ogawa and Inaba cholera vaccines in rural Bangladesh--three years of observation.

Authors:  W H Mosley; K M Aziz; A S Rahman; A K Chowdhury; A Ahmed
Journal:  Bull World Health Organ       Date:  1973       Impact factor: 9.408

View more
  32 in total

1.  Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial.

Authors:  K L Kotloff; S S Wasserman; S O'Donnell; G A Losonsky; S J Cryz; M M Levine
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

2.  Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin.

Authors:  R K Gupta; S C Szu; R A Finkelstein; J B Robbins
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

3.  Preliminary assessment of the safety and immunogenicity of live oral cholera vaccine strain CVD 103-HgR in healthy Thai adults.

Authors:  S Migasena; P Pitisuttitham; B Prayurahong; P Suntharasamai; W Supanaranond; V Desakorn; U Vongsthongsri; B Tall; J Ketley; G Losonsky
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

Review 4.  Recent progress in mucosal vaccine development: potential and limitations.

Authors:  Nils Lycke
Journal:  Nat Rev Immunol       Date:  2012-07-25       Impact factor: 53.106

5.  Human immune response to Vibrio cholerae O1 whole cells and isolated outer membrane antigens.

Authors:  K Richardson; J B Kaper; M M Levine
Journal:  Infect Immun       Date:  1989-02       Impact factor: 3.441

6.  Experimental non-O group 1 Vibrio cholerae gastroenteritis in humans.

Authors:  J G Morris; T Takeda; B D Tall; G A Losonsky; S K Bhattacharya; B D Forrest; B A Kay; M Nishibuchi
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

7.  Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques.

Authors:  M M Levine; J B Kaper; D Herrington; G Losonsky; J G Morris; M L Clements; R E Black; B Tall; R Hall
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

8.  Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen.

Authors:  K L Kotloff; D A Herrington; T L Hale; J W Newland; L Van De Verg; J P Cogan; P J Snoy; J C Sadoff; S B Formal; M M Levine
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

9.  Cell-associated hemagglutinin-deficient mutant of Vibrio cholerae.

Authors:  T M Finn; J Reiser; R Germanier; S J Cryz
Journal:  Infect Immun       Date:  1987-04       Impact factor: 3.441

10.  Compared colonizing and immunizing efficiency of toxinogenic (A+ B+) Vibrio cholerae and an A- B+ mutant (Texas Star-SR) studied in adult rabbits.

Authors:  E Tokunaga; W C Cray; N F Pierce
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.